Sotio

Sotio Biotech is a Czech clinical-stage biotechnology company focused on the discovery and development of oncology medicines. Its research is centered on next-generation cancer immunotherapies and antibody-drug conjugates (ADCs), with programs spanning preclinical research and clinical testing. The company operates internationally, maintaining a principal base in Prague and offices or operations in Basel, Switzerland, and Boston, United States. Sotio was founded in 2010 and became part of PPF Group in 2012. PPF is the investment group established by Petr Kellner. Sotio's development model combines internal research and development with external collaborations and biotechnology investments. Its work is directed primarily at solid tumors and at therapeutic approaches intended to improve the activity, selectivity, or durability of anticancer treatment. One of the company's principal immuno-oncology programs is SOT201, an immunocytokine that combines a proprietary interleukin-15 superagonist with an antibody directed at PD-1. The design is intended to concentrate an attenuated IL-15 agonist around PD-1-positive immune cells, particularly CD8-positive T cells. Sotio describes the program as being aimed at stimulating antitumor immunity and addressing tumors in which T cells have become dysfunctional or exhausted. SOT201 entered clinical development in May 2024 through the Phase 1 VICTORIA-01 study. Sotio also develops ADCs, which attach cytotoxic payloads to antibodies directed at selected tumor-associated targets. The company has built this part of its pipeline through collaborations with Biocytogen, Synaffix, LigaChem Biosciences, and NBE-Therapeutics. Its more advanced ADC candidates include SOT109, an anti-CDH17 program being developed for colorectal cancer, and SOT106, an anti-LRRC15 program being developed for LRRC15-positive sarcomas and other solid tumors. In addition to its own pipeline, Sotio has participated in the broader PPF biotechnology investment portfolio. PPF and Sotio were associated with NBE-Therapeutics, an ADC developer, before PPF sold its stake in that company to Boehringer Ingelheim at the end of 2020. Sotio has also managed PPF investments in Autolus Therapeutics and Cellestia Biotech. These activities place the company at the intersection of drug development, strategic partnering, and biotechnology investment rather than positioning it as a commercial pharmaceutical manufacturer. Sotio remains a development-stage organization. The available reference material does not identify approved products, commercial sales, public-market securities, or a definitive date for commercialization. Its current identity is therefore defined by its oncology pipeline, international research footprint, clinical trials, and relationship with PPF Group.

Sotio Biotech was established in 2010 as a biotechnology company pursuing oncology research. From its early period, the company developed an emphasis on cancer immunology and on translating research concepts into drug candidates. Radek Špíšek has been associated with the organization since its beginning, initially serving as Chief Scientific Officer before becoming Chief Executive Officer. A major ownership milestone came in 2012, when Sotio became part of PPF Group, the investment group established by Petr Kellner. The relationship gave Sotio a place within a broader investment and operating platform while allowing it to continue building its own oncology research capabilities. Rather than operating as a traditional commercial pharmaceutical company, Sotio has remained focused on research, development, partnerships, and portfolio construction. The company expanded its international presence through operations in Prague, Basel, and Boston. Its scientific and business activities have covered both internally developed programs and collaborations with outside technology and drug-development companies. This approach has been particularly visible in its ADC work, where Sotio has collaborated with Biocytogen, Synaffix, LigaChem Biosciences, and NBE-Therapeutics. The objective of these programs is to combine tumor-targeting antibodies with potent drug payloads and other enabling technologies for the treatment of solid tumors. Sotio's immunotherapy pipeline includes SOT201, an immunocytokine built from a proprietary IL-15 superagonist linked to an anti-PD-1 antibody. The candidate is designed to act preferentially on PD-1-positive immune cells, including CD8-positive T cells, with the aim of stimulating antitumor responses and addressing immune-cell exhaustion. SOT201 entered the clinic in May 2024 in the Phase 1 VICTORIA-01 trial, marking a transition from laboratory and preclinical development to human testing. The ADC portfolio includes SOT109, an anti-CDH17 candidate being developed for colorectal cancer, and SOT106, an anti-LRRC15 candidate intended for LRRC15-positive sarcomas and other solid tumors. These programs illustrate Sotio's concentration on targeted approaches for cancers that may benefit from selective delivery of cytotoxic agents. Sotio has also participated in biotechnology investment activity managed with or for PPF. At the end of 2020, PPF sold its stake in NBE-Therapeutics to Boehringer Ingelheim. The transaction highlighted the commercial interest in ADC platforms and was relevant to Sotio's wider portfolio strategy. Sotio has additionally managed PPF investments in Autolus Therapeutics and Cellestia Biotech. The available reference material presents Sotio as an active, clinical-stage oncology biotechnology company. It does not document an approved medicine, a commercial product launch, public listing, or financial performance. The company's current history is therefore principally a history of scientific pipeline development, international expansion, corporate ownership under PPF, clinical translation, and strategic participation in the biotechnology ecosystem.

• 2024

  SOT201 entered clinical testing

  [1]Sotioen.wikipedia.org

  SOT201 entered the clinic in May 2024 in the Phase 1 VICTORIA-01 trial.

• 2020

  PPF divested its NBE-Therapeutics stake

  [1]Sotioen.wikipedia.org

  PPF sold its stake in NBE-Therapeutics to Boehringer Ingelheim, highlighting the strategic value of ADC biotechnology in the portfolio.

• 2012

  Joined PPF Group

  [1]Sotioen.wikipedia.org

  Sotio became part of PPF Group, the investment group established by Petr Kellner.

• 2010

  Sotio founded

  [1]Sotioen.wikipedia.org

  Sotio was established as a biotechnology company focused on oncology research and development.

A PPF-backed, internationally operating clinical-stage biotechnology company focused on innovative treatments for solid tumors, especially immune-cell activating therapies and targeted antibody-drug conjugates.

• Immunocytokine · 2024

  SOT201

  SOT201 is an immunocytokine that fuses a proprietary IL-15 superagonist with an antibody targeting PD-1. Its intended mechanism is cis-acting activation of PD-1-positive immune cells, particularly CD8-positive T cells, with the goal of producing stronger antitumor activity and reinvigorating exhausted T cells. The candidate entered clinical development in May 2024 in the Phase 1 VICTORIA-01 study.

• Antibody-drug conjugate

  SOT109

  SOT109 is an anti-CDH17 antibody-drug conjugate under development for colorectal cancer. It belongs to Sotio's targeted ADC portfolio, which is intended to direct potent drug payloads toward tumor-associated biological targets. The available reference material identifies SOT109 as one of the company's two more advanced ADC therapeutic candidates but does not provide a commercial launch date.

• Antibody-drug conjugate

  SOT106

  SOT106 is an anti-LRRC15 antibody-drug conjugate being developed for LRRC15-positive sarcomas and other solid tumors. The program forms part of Sotio's strategy of using targeted antibody-payload constructs against selected tumor types. The source material describes it as one of the company's more advanced ADC candidates, without specifying an approval or commercial availability date.

• 2024

  SOT201 advanced into first-in-human testingProduct launch

  Background

  SOT201 had been developed as a PD-1-targeted IL-15 immunocytokine for oncology treatment.

  Action taken

  Sotio initiated clinical development of SOT201 through the Phase 1 VICTORIA-01 trial in May 2024.

  Aftermath

  SOT201 became a clinical-stage program, although the available material does not report trial outcomes.

  Source

• 2020

  PPF sold its stake in NBE-TherapeuticsM&A

  Background

  NBE-Therapeutics was developing antibody-drug conjugates for solid tumors, an area connected to Sotio's strategic biotechnology interests.

  Action taken

  At the end of 2020, PPF sold its stake in NBE-Therapeutics to Boehringer Ingelheim.

  Aftermath

  The transaction demonstrated the strategic and commercial interest in ADC technology while Sotio continued developing its own ADC pipeline.

  Source

• 2012

  Sotio became part of PPF GroupStrategy

  Background

  Sotio was an emerging oncology biotechnology company seeking to develop research programs and expand its capabilities.

  Action taken

  The company joined PPF Group, creating a relationship with a larger investment platform while retaining its biotechnology development focus.

  Aftermath

  Sotio continued developing oncology programs and participating in PPF's broader biotechnology investment activities.

  Source

• 2020-08-31

  SOTIO acquires rights to Unum Therapeutics’ BOXR platform[3]SOTIO收购Unum Therapeutics的BOXR平台权利finanznachrichten.de

  Reported: 2020-08-31

  SOTIO announced that it had acquired the rights to Unum Therapeutics’ BOXR cell therapy platform and lead programs for $11.5 million, including an $8.1 million upfront payment and up to $3.4 million in milestone payments.

1. 1Sotioen.wikipedia.org
2. 2Sotio Biotech official websitesotio.com
3. 3SOTIO收购Unum Therapeutics的BOXR平台权利finanznachrichten.de